Brief: Autolus Therapeutics Announces Data From Auto1/22 Trial
26/04/2023 12:11
April 26 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS ANNOUNCES DATA FROM AUTO1/22 TRIAL IN
PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN AN ORAL PRESENTATION
AT EBMT 49TH ANNUAL MEETING
Source text for Eikon: ID:nGNX3gxVc9
Further company coverage: AUTL.O
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants